Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 139 for “"basal-like"”.
-
Hippo pathway Inactivation drives basal-like mammary tumorigenesis
Basal-like breast cancers make up an aggressive subtype of breast cancer with diverse intratumor cell heterogeneity and poor clinical outcomes. These cancers are predominantly triple-negative cancers such that they lack expression of estrogen receptor, progesterone receptor, and human epidermal …
-
Clinical utility of biomarkers for basal-like breast cancer
… growth factor receptor-2 (Her2)-Enriched and basal-like has remarkably advanced breast cancer diagnosis, treatment, and outcome. However, comparatively few advancements have been made in identifying biomarkers that can tailor treatments for the aggressive basal-like subtype. This group is …
-
Revealing Putative Drug Targets for Basal-Like Breast Cancer
… has limited treatment options for patients with Basal-like breast cancer to non-selective cytotoxic and cytostatic drugs. This research aimed to reveal putative drug targets for Basal-like breast cancer. The advances of sequencing technologies and computational methods have benefited drug target …
-
IGF2 Promotes Activation of Estrogen Receptors in Basal-like Breast Cancer Cells
… breast cancer (BC) progression. Basal-like BC (BLBC) is a sub-group of estrogen-independent tumors that have a very aggressive clinical behavior and are resistant to hormone-based therapy resulting in reduced disease-free survival period and increasing the mortality of breast …
-
Cytotoxic Activity of Sphingosine-1-Phosphate against Human Triple-negative/ Basal-like Breast Cancer
… (TNBC), does not respond to hormonal therapy. Basal-like breast cancer (BLBC) has shorter overall survival rate among other subtypes. Tumors sharing both TNBC and BLBC are considered less responsive to currently available treatment. Chemoresistance to treatment has been a challenge in cancer …
-
Pre-clinical trials with precision-medicine based therapeutics in basal-like patient-derived xenografts
… progesterone receptor, or are positive for HER2. Basal-like breast cancer tends to not have these biomarkers, which necessitates their treatment to be traditional, untargeted therapeutics which are less effective and tend to have harsh adverse effect profiles – this is an important unmet need. …
-
The Role of MicroRNAs in the Fibroblasts of Triple Negative and Basal-like Breast Cancer
… influence on tumour behaviour and prognosis. The basal-like subtype, which is typically – but not always – triple negative for receptor expression status limiting treatment options, represents one of the main subtypes with relatively poor prognosis. Breast cancer is a disease that comprises not …
-
Investigating the Mechanisms of Resistance to Dual PI3K/MTOR Inhibitor in PIK3CA Mutant Basal Like Bladder Cancer
… status as well as tumor subtype (luminal-like or basal-like) play cooperative role in driving treatment response, where PIK3CA E542K mutation in basal-like tumors is associated with resistance to PI3K inhibition. Resistance is driven by feedback activation of alternative feedback signaling …
-
Inhibitor of Differentiation 4: a new player in the DNA damage repair pathway in basal-like breast cancer
Basal-like breast cancer (BLBC) is a poorly characterised, heterogeneous disease. Patients are diagnosed with aggressive, high-grade tumours and often relapse with chemotherapy resistance. Poor survival is compounded by a lack of targeted treatments. Detailed understanding of the molecular …
-
KPT-330 synergizes with everolimus to reduce mTORC1-overactive basal-like triple-negative breast cancer brain metastasis burden
… 20% of all breast cancer diagnoses. Basal-like TNBC is notably difficult to treat due to the lack of actionable drug targets such as estrogen and progesterone receptors, as well as HER2. Due to the deficiency in TNBC-targeting drugs that are able to cross the blood-brain barrier (BBB) …
-
Vestigial-Like 1 Is A Shared Targetable Cancer-Placenta Antigen Expressed By Pancreatic and Basal-Like Breast Cancers
… from co-transcriptional activator Vestigial-like 1 (VGLL1), a novel putative TAA demonstrating overexpression in multiple tumor types and low or absent transcript expression in normal tissues with the exception of placenta. VGLL1-specific CTL isolated and expanded from the blood of a male …
-
The chemokine CCL2/CCR2 signaling mediates cancer associated fibroblasts-cancer cells interaction and promotes basal-like breast cancer progression
… diagnosed in women in the United States. The basal-like breast cancer subtype represents about 12% of breast cancer and has the worst outcome in patients due to lack of effective therapies. Tumor stroma plays an important role in cancer progression. Cancer associated fibroblasts (CAFs) are the …
-
The covalent JNK inhibitor, JNK-in-8, synergizes with lapatinib to cause cell death in basal-like breast cancer cell lines
Basal-like and Claudin-low breast cancers have the worst prognosis and represent 15-20% of breast cancers diagnosed each year. Endocrine and molecularly targeted therapies are ineffective for these tumors due to lack of Estrogen Receptor (ER) or Human Epidermal Growth Factor Receptor 2 (HER2) …
-
Investigation Of Death Receptor-5 Mediated Apoptosis And Inhibition Of Wnt/ß-Catenin Signaling In Basal-Like Breast Cancer Stem Cells
Basal-like breast cancers (BLBC) display aggressive clinical behavior attributed to the presence of cancer stem cells (CSCs). TRA-8, a monoclonal antibody that binds specifically to TRAIL death receptor 5, preferentially induces apoptosis in BLBC subtype cells; however it is unknown if TRA-8 is …
-
Clinical performance of diagnostic, prognostic and predictive immunohistochemical biomarkers for hormone receptor-negative breast cancer
… particularly aggressive subtype referred to as “basal-like”, which comprises ~15% of all cases, afflicts younger women and is refractory to endocrine and anti-HER2 therapies. Immunohistochemical surrogate definitions for basal-like breast cancer, such as the ER/PR/HER2 triple negative phenotype …
-
Η ανοσοϊστοχημική μελέτη των ανδρογονικών αποδοχέων (AR) και της ενζυμικής αρωματάσης (P450 AROM), σε ασθενείς με καρκίνο μαστού βασικού τύπου (Basal Like Breast Cancer) και τριπλή αρνητική έκφραση, ανοσοϋποδοχέων: ER/PGR/HER2 (Triple Negative Breast Cancer Tumors): εργαστηριακή διερεύνηση και κλινική-θεραπευτική συσχέτιση
In light of the controversial published literature, this thesis aims to examine the potential prognostic role of androgen receptor (AR) immunohistochemical expression in triple negative breast cancer (TNBC). Ninety patients with TNBC were included in this thesis; the associations between AR …
Page 1 of 7